论文部分内容阅读
目的 :研究普伐他汀对高脂血症病人降脂作用及对血浆D 二聚体的影响。方法 :高脂血症病人 36例 ,服用普伐他汀 10mg·d- 1,服药 4wk后若血清TC >5.2mmol·L- 1,则剂量加倍 ,疗程 12wk。服药前后每 4wk测TC ,TG ,HDL C ,LDL C及D 二聚体。结果 :治疗 12wk ,普伐他汀降低TC ,TG的总有效率分别为 94 %和 59% ,升高HDL C的总有效率为 54%。治疗 12wk后TC ,TG ,LDL C ,D 二聚体分别下降 ( 2 6± 12 ) % ,( 2 4± 2 0 ) % ,( 2 7±18) % ,( 4 0± 17) % ,HDL C上升 ( 15± 3) % ,差异有非常显著意义 (P <0 .0 1)。结论 :普伐他汀能够降低TC ,TG和LDL C ,升高HDL C ,且能降低血浆D 二聚体水平 ,从而改善凝血、纤溶系统的紊乱
Objective: To study the effect of pravastatin on lipid-lowering effect on plasma D-dimer in patients with hyperlipidemia. Methods: Thirty six patients with hyperlipidemia were treated with pravastatin 10 mg · d-1. After four weeks of treatment, serum TC> 5.2 mmol·L-1 was doubly dosed for 12 weeks. TC, TG, HDL C, LDL C and D dimers were measured every 4 weeks before and after taking the medicine. Results: After 12 weeks of treatment, the total effective rate of pravastatin in lowering TC and TG were 94% and 59%, respectively. The total effective rate of raising HDL C was 54%. The levels of TC, TG, LDL C and D dimers decreased by (12 ± 12)%, (24 ± 20)%, (27 ± 18)%, (40 ± 17)%, C (15 ± 3)%, the difference was significant (P <0.01). Conclusion: Pravastatin can reduce TC, TG and LDL C, increase HDL C, and reduce plasma D dimer level, thus improving the coagulation and fibrinolytic system disorders